GLTOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:31):

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases...

Stats
本日の出来高	76 539.00
平均出来高	217 082
時価総額	18.88M
EPS	$0 ( 2024-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0100 (1.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Schambye Hans T.	Buy	200 000	Restricted Stock Units
2024-01-03	Winslow Garrett	Buy	100 000	Restricted Stock Units
2024-01-03	Freve Jonathan	Buy	100 000	Restricted Stock Units
2023-08-15	Orbimed Advisors Llc	Sell	535 534	Common Stock
2023-08-15	Orbimed Advisors Llc	Sell	248 819	Common Stock

INSIDER POWER
-13.15
Last 96 transactions
Buy: 4 275 597 \| Sell: 1 504 628

ボリューム相関

長: -0.10 (neutral)

短: 0.20 (neutral)

Signal:(54.38) Neutral

Galecto, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Galecto, Inc. 相関 - 通貨/商品

0.27
( neutral )

0.49
( neutral )

0.00
( neutral )

0.25
( neutral )

Galecto, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-830 000 (0.00 %)
EPS:	$-1.440

FY	2023
収益:	$0
総利益:	$-830 000 (0.00 %)
EPS:	$-1.440

FY	2022
収益:	$0
総利益:	$-490 000 (0.00 %)
EPS:	$-2.44

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.05

Financial Reports:

No articles found.

Galecto, Inc.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.